
ATANASIO
PANDIELLA ALONSO
Investigador
Publications (275) ATANASIO PANDIELLA ALONSO publications
2025
-
DNA Damage Underlies the Cytotoxic and Apoptotic Effects of Selected Ethiopian Medicinal Plants against Cancer Cell Lines
Journal of Pharmacology and Pharmacotherapeutics
2024
-
Action Mechanism of Bioactive Compounds from Plants and Spices Mixture as Promising Anticancer Agents: In Silico Drug Design Predictions Targeting Cancer Cell Proliferation Through Cell Cycle Arrest Pathway
Journal of Computational Biophysics and Chemistry
-
ERK5 Interacts with Mitochondrial Glutaminase and Regulates Its Expression
International Journal of Molecular Sciences, Vol. 25, Núm. 6
-
Latent-Transforming Growth Factor β-Binding Protein 1/Transforming Growth Factor β1 Complex Drives Antitumoral Effects upon ERK5 Targeting in Melanoma
American Journal of Pathology, Vol. 194, Núm. 8, pp. 1581-1591
-
Multiple mechanisms contribute to acquired TRAIL resistance in multiple myeloma
Cancer Cell International, Vol. 24, Núm. 1
-
Ocoxin Oral Solution Triggers DNA Damage and Cell Death in Ovarian Cancer
Nutrients, Vol. 16, Núm. 15
-
Peptidylarginine deiminase 3 modulates response to neratinib in HER2 positive breast cancer
Oncogenesis, Vol. 13, Núm. 1
-
Strategies to boost antibody selectivity in oncology
Trends in Pharmacological Sciences, Vol. 45, Núm. 12, pp. 1135-1149
-
Synergistic effects of medicinal plants in combination with spices from algeria: Anticancer, antiangiogenic activities, and embrytoxicity studies
Journal of Ethnopharmacology, Vol. 330
-
T-reg transcriptomic signatures identify response to check-point inhibitors
Scientific Reports, Vol. 14, Núm. 1
-
Trastuzumab deruxtecan in breast cancer
Critical Reviews in Oncology/Hematology, Vol. 198
-
Understanding the Preclinical Efficacy of Antibody–Drug Conjugates
International Journal of Molecular Sciences, Vol. 25, Núm. 23
2023
-
An amino acid transporter subunit as an antibody-drug conjugate target in colorectal cancer
Journal of experimental & clinical cancer research : CR, Vol. 42, Núm. 1, pp. 200
-
An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs
Cancer Letters, Vol. 554
-
Chemical-proteomics Identify Peroxiredoxin-1 as an Actionable Target in Triple-negative Breast Cancer
International Journal of Biological Sciences, Vol. 19, Núm. 6, pp. 1731-1747
-
Considerations for the clinical development of immuno-oncology agents in cancer
Frontiers in immunology, Vol. 14, pp. 1229575
-
Etiopathogenic role of ERK5 signaling in sarcoma: prognostic and therapeutic implications
Experimental and Molecular Medicine, Vol. 55, Núm. 6, pp. 1247-1257
2022
-
Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer
International Journal of Molecular Sciences, Vol. 23, Núm. 10
-
ERK5 Is a Major Determinant of Chemical Sarcomagenesis: Implications in Human Pathology
Cancers, Vol. 14, Núm. 14
-
Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers
Cancers, Vol. 14, Núm. 18